Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor.
Prulière-Escabasse
Virginie
V
Gomez-Roca
Carlos
C
Escudier
Estelle
E
Coste
André
A
Besse
Benjamin
B
Massard
Christophe
C
Soria
Jean-Charles
JC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004724:Endoscopy; D004844:Epistaxis / Q000139:chemically induced / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009297:Nasal Mucosa / Q000187:drug effects / Q000473:pathology; D015508:Nasal Obstruction / Q000139:chemically induced / Q000473:pathology; D009367:Neoplasm Staging; D012220:Rhinitis / Q000139:chemically induced*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014420:Turbinates / Q000187:drug effects / Q000473:pathology
C546842:MTOR protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases